REN and Hyperkalemia: MRAs such as finerenone are known to increase serum potassium levels, but early combination with either an SGLT2i22 or ARNI23 (when switched from a renin–angiotensin system inhibitor) may attenuate risks of hyperkalemia, suggesting that these combinations may in fact be safer.